Two VEGFR3 missense polymorphisms, VEGFR3 rs307821 (R1324L) and VEGFR3 rs307826 (T494A), showed a trend toward reduced PFS in GEP NETs (HR: 12.3; 95% CI 1.09โ139ยท2; P = 0.042 and HR: 6.9; 95% CI 0.96โ49.9; P = 0.055...Pazopanib showed clinical activity in patients with advanced NETs regardless of previous treatments.